



MediWound to Report First Quarter 2026 Financial Results

May 7, 2026

MediWound to Report First Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time

YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the first quarter ended March 31, 2026 on Wednesday, May 27, 2026.

Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call & Webcast Details

Toll-Free: 1-844-676-8833

Israel: 1-809-212373

International: 1-412-634-6869

Webcast: [Click HERE](#)

To access the call, participants should dial the applicable telephone number above **at least 5 minutes** prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company's FDA-approved biologic, NexoBrid[®], is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound's late-stage pipeline product, EscharEx[®], is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on [LinkedIn](#) and [X \(formerly Twitter\)](#).

MediWound Contacts:

Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com

Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com